RESEARCHER PROFILE

Eric P. Winer

← Back to Harvard University

E

Harvard University

Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchBRCA gene mutations in cancerBreast Lesions and Carcinomas

Eric P. Winer works in Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, BRCA gene mutations in cancer, Breast Lesions and Carcinomas. Recorded institutional associations include Harvard University, Yale Cancer Center, Yale University.

1,620Publications
128,837Citations
171H-index

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Breast Cancer Treatment

    2019 · 4,804 citations

  2. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

    2018 · 4,342 citations

  3. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    2013 · 3,746 citations

  4. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    2016 · 2,033 citations

  5. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    2016 · 2,020 citations

  6. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

    2005 · 1,887 citations

  7. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

    2015 · 1,827 citations

  8. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    2003 · 1,564 citations

  9. CDK4/6 inhibition triggers anti-tumour immunity

    2017 · 1,502 citations

  10. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    2009 · 1,407 citations

  11. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

    2020 · 1,356 citations

  12. Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

    2003 · 1,320 citations

  13. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

    2019 · 1,320 citations

  14. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

    2013 · 1,310 citations

  15. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    2019 · 1,212 citations

  16. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    2017 · 1,205 citations

  17. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

    2018 · 1,171 citations

  18. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

    2016 · 1,127 citations

  19. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    2017 · 1,118 citations

  20. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

    2015 · 1,082 citations

  21. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer

    2004 · 1,078 citations

  22. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

    2017 · 1,051 citations

  23. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

    2004 · 1,031 citations

  24. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

    2014 · 1,013 citations

  25. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

    2010 · 981 citations

← Return to the university profile